Xenetic Biosciences Inc (NASDAQ:XBIO) has a beta value of 2.29 and has seen 1.63 million shares traded in the recent trading session. The company, currently valued at $6.72M, closed the recent trade at $4.36 per share which meant it gained $1.22 on the day or 38.63% during that session. The XBIO stock price is -19.27% off its 52-week high price of $5.20 and 49.54% above the 52-week low of $2.20. If we look at the company’s 10-day average daily trading volume, we find that it stood at 58100.0 shares traded. The 3-month trading volume is 17.08K shares.
Xenetic Biosciences Inc (NASDAQ:XBIO) trade information
Sporting 38.63% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the XBIO stock price touched $4.36 or saw a rise of 17.27%. Year-to-date, Xenetic Biosciences Inc shares have moved 9.27%, while the 5-day performance has seen it change 59.12%. Over the past 30 days, the shares of Xenetic Biosciences Inc (NASDAQ:XBIO) have changed 43.15%. Short interest in the company has seen 3494.0 shares shorted with days to cover at 0.44.
Xenetic Biosciences Inc (XBIO) estimates and forecasts
The company’s shares have gained 7.26% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 5.70%.
1 analysts offering their estimates for the company have set an average revenue estimate of 482k for the current quarter. 1 have an estimated revenue figure of 542k for the next ending quarter. Year-ago sales stood 566.48k and 481.83k respectively for this quarter and the next, and analysts expect sales will shrink by -14.91% for the current quarter and 5.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 47.32% over the past 5 years. Earnings growth for 2025 is a modest 0.39% while over the next 5 years, the company’s earnings are expected to increase by 44.90%.
XBIO Dividends
Xenetic Biosciences Inc is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Xenetic Biosciences Inc (NASDAQ:XBIO)’s Major holders
Insiders own 19.05% of the company shares, while shares held by institutions stand at 7.61% with a share float percentage of 9.40%. Investors are also buoyed by the number of investors in a company, with Xenetic Biosciences Inc having a total of 15.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 0.64% shares in the company for having 9.8 shares of worth $38747.0 while later fund manager owns 6.83 shares of worth $27032.0 as of Apr 30, 2025 , which makes it owner of about 0.44% of company’s outstanding stock.
